Literature DB >> 7828280

The role of methoxymorpholino anthracycline and cyanomorpholino anthracycline in a sensitive small-cell lung-cancer cell line and its multidrug-resistant but P-glycoprotein-negative and cisplatin-resistant counterparts.

W T van der Graaf1, N H Mulder, C Meijer, E G de Vries.   

Abstract

The cytotoxic action of two morpholino anthracyclines, methoxymorpholino anthracycline (MRA-MT, FCE 23,762) and cyanomorpholino anthracycline (MRA-CN), was compared with the cytotoxicity of doxorubicin (DOX), the topoisomerase II inhibitor etoposide (VP-16), the topoisomerase I inhibitor camptothecin, methotrexate, and cisplatin in GLC4, a human small-cell lung-cancer cell line, in GLC4-Adr, its P-glycoprotein (Pgp)-negative, multidrug-resistant (MDR; 100-fold DOX-resistant) subline with overexpression of the MDR-associated protein (MRP) and a lowered topoisomerase II activity, and in GLC4-CDDP, its cisplatin-resistant subline. GLC4-Adr was about 2-fold cross-resistant for the morpholino anthracyclines and GLC4-CDDP was, relative to GLC4, more resistant for the morpholino anthracyclines than for DOX. Overall, MRA-CN was about 2.5-fold more cytotoxic than MRA-MT. The cytotoxicity profile of the morpholino anthracyclines in these cell lines mimicked that of camptothecin.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7828280     DOI： 10.1007/BF00689457

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  32 in total

1.  Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin.

Authors:  D H Lau; K L Ross; B I Sikic
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

2.  Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.

Authors:  D H Lau; A D Lewis; M N Ehsan; B I Sikic
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

3.  Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.

Authors:  K Wassermann; J Markovits; C Jaxel; G Capranico; K W Kohn; Y Pommier
Journal:  Mol Pharmacol       Date:  1990-07       Impact factor: 4.436

4.  Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog.

Authors:  B I Sikic; M N Ehsan; W G Harker; N F Friend; B W Brown; R A Newman; M P Hacker; E M Acton
Journal:  Science       Date:  1985-06-28       Impact factor: 47.728

5.  Comparative cytotoxicities of various morpholinyl anthracyclines.

Authors:  D G Streeter; D L Taylor; E M Acton; J H Peters
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

6.  DNA cross-linking and cytotoxicity of the alkylating cyanomorpholino derivative of doxorubicin in multidrug-resistant cells.

Authors:  S A Scudder; J M Brown; B I Sikic
Journal:  J Natl Cancer Inst       Date:  1988-10-19       Impact factor: 13.506

7.  Selective inhibition of human ribosomal gene transcription by the morpholinyl anthracyclines cyanomorpholinyl- and morpholinyldoxorubicin.

Authors:  K Wassermann; R A Newman; F M Davis; T D Mullins; K M Rose
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701

8.  Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line.

Authors:  S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

9.  Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.

Authors:  S de Jong; J G Zijlstra; E G de Vries; N H Mulder
Journal:  Cancer Res       Date:  1990-01-15       Impact factor: 12.701

10.  In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.

Authors:  M Ripamonti; G Pezzoni; E Pesenti; A Pastori; M Farao; A Bargiotti; A Suarato; F Spreafico; M Grandi
Journal:  Br J Cancer       Date:  1992-05       Impact factor: 7.640
View more
  2 in total

1.  Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.

Authors:  M Bakker; J P Droz; A R Hanauske; J Verweij; A T van Oosterom; H J Groen; M A Pacciarini; L Domenigoni; F van Weissenbruch; E Pianezzola; E G de Vries
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

2.  A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.

Authors:  E Fokkema; J Verweij; A T van Oosterom; D R Uges; R Spinelli; O Valota; E G de Vries; H J Groen
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.